← SynDRA
TIVANTINIB
SynDRA canonical compound SYN0030080 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | MET |
|---|
| Mechanism of action | Tyrosine kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- tyrosine kinase inhibitor
- MET INHIBITOR
- Hepatocyte growth factor receptor inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- OPA1
- HMOX2
- SYK
- EIF5B
- AAK1
- PASK
- PFKP
- PEBP1
- PDXK
- PDGFRB
- PAK6
- PHKG2
- PAK4
- PAK2
- PAICS
- OLA1
- NTRK1
- PGRMC1
- PIM1
- NLK
- PRKACB
- PRKCD
- PRKCB
- PRKCA
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACA
- PIM2
- PRKAA1
- PLK4
- PKN2
- PKN1
- PKMYT1
- PIP4K2C
- NQO2
- NEK7
- NEK9
- MAPK3
- MAPKAPK5
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- ARQ-197
- ARQ 197
- ARQ197
- Tivantinib (ARQ-197)
- (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione
- UNII-PJ4H73IL17
- PJ4H73IL17
- (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione
- Tivantinib [USAN:INN]
- ARQ 197, Tivantinib
- ARQ 197 (Tivantinib)
- cc-86
- SCHEMBL44944
- Tivantinib (JAN/USAN/INN)
- GTPL7948
- CHEMBL2103882
- CHEBI:91398
- QCR-102
- Tivantinib (ARQ 197)
- rel-(3R,4R)-3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-2,5-pyrrolidinedione
- Tivantinib [INN]
- Tivantinib; ARQ197
- TIVANTINIB [MI]
- TIVANTINIB [JAN]
- TIVANTINIB [USAN]
- TIVANTINIB [WHO-DD]
- DTXSID60920316
- ARQ-197,Tivantinib, ARQ197
- ARQ197; ARQ-197;Tivantinib
- BCPP000042
- BCP02529
- EX-A2169
- CAS:905854-02-6;Tivantinib
- BDBM50146168
- MFCD11977596
- NSC758242
- NSC800951
- s2753
Look up TIVANTINIB in the interactive SynDRA portal →